CHEK2 and breast cancer: Thus, in this study we used WES to disclose variants contributing to BC increased risk in patients that were negative for pathogenic variants in three major BC genes—BRCA1/2 and TP53 genes—and the most common point mutation in CHEK2 gene (c.1100delC).